Le Lézard
Classified in: Health
Subject: SVY

Europe Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets 2021: Supplier Shares, Country Forecasts, Emerging Technologies, Competitive Landscape


NEW YORK, Nov. 17, 2017 /PRNewswire/ -- Complete report $4,850.  DataPack (test volumes, sales forecasts, supplier shares) $2,850The report is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget.

Read the full report: https://www.reportlinker.com/p05121976

This new five-country study from LeadingMarketResearch contains 495 pages, 28 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Report Highlights

- Market shares of leading suppliers

- Business and technological trends in major markets

- Five-year test volume and sales forecasts

- Market shares of leading competitors

- Feature comparison of major analyzers

- Strategic profiles of leading market players and start-up firms developing innovative products

- Specific product and business opportunities for instrument and consumable suppliers.

Rationale

Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry.  The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches.  The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.  In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies.  Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Geographic Coverage

- France

- Germany

- Italy

- Spain

- UK

European Market Overview

- Laboratories performing DNA sequencing and molecular diagnostic testing by country and market segment.

- Five-year test volume and sales projections by country.

Market Segmentation Analysis

- Five-year test volume and sales projections:

- Infectious Diseases        - Forensic Testing

- Cancer                            - Paternity Testing/HLA Typing

- Genetic Diseases            - Others

- A comprehensive analysis of the sequencing market by country and laboratory segment.

- Detailed market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and major suppliers by country.

Product/Technology Review

- Comparison of the major molecular diagnostic analyzers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and target/signal amplification methods.

- Worldwide listings of companies, universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in RandD.

   - Abbott

   - Affymetrix

   - Agilent Technologies

   - Applied Gene Technologies

   - Arca Biopharma

   - Beckman Coulter/Danaher

   - Becton Dickinson

   - Biokit

   - BioMerieux

   - Bio-Rad

   - Biotest

   - Cepheid

   - CellMark Forensics/LabCorp

   - Decode Genetics

   - Diadexus

   - Eiken

   - Elitech Group

   - Enzo

   - Exact Sciences

   - Fujirebio

   - Grifols

   - Hologic/Gen-Probe

   - Illumina

   - Kreatech/Leica

   - Li-Cor Biosciences

   - Life Technologies/Thermo Fisher

   - Monogram Biosciences

   - Myriad Genetics

   - Ortho-Clinical Diagnostics

   - Perkin Elmer/Caliper

   - Proteome Sciences

   - Qiagen              

   - Roche

   - Scienion

   - Sequenom

   - Shimadzu

   - Siemens

   - Sierra Molecular

   - Takara Bio

   - Tecan Group

   - Thermo Fisher

- Comprehensive listings of companies developing and marketing molecular diagnostic products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Contains 495 pages and 28 tables


Read the full report: https://www.reportlinker.com/p05121976

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...

at 07:00
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...



News published on and distributed by: